Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in pediatric fibrosing interstitial lung disease
2018-004530-14Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in pulmonary fibrosis (PF), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), sponsored by Boehringer Ingelheim. Started Aug 2019; status: active.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
Beyond the preview
Go deeper on 2018-004530-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004530-14.